Finasteride, a common hormone-blocking drug, reduces men’s risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
